ArkBio Initiates Phase II Clinical Trial of AK0610
Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced the initiation of a Phase II clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection.
The study is a multicenter, randomized, double-blind, placebo-controlled, dose-escalation phase II trial that will assess the safety, tolerability, and pharmacokinetics of AK0610 Injection in healthy infants in China.
Author's summary: ArkBio starts Phase II trial for RSV preventive antibody.
More News
- CNN announces election night coverage plans, including All Access-only ‘livecast’
- How Discrimination and Stress Impact the Mental Health of Young Sexual Minority Men
- Ahsoka Season 2 Gets Exciting Update From Rosario Dawson
- Emmy-Winner Chronicles Yankees Icon Joe Torre’s MLB Legacy On Screen
- Integra stock dips on lowered guidance after Q3 sales miss
- Trump Goes Full Dictator With Bonkers Threat to Use Air Force and Navy in U.S. Cities
- NBA head coach Tyronn Lue allegedly attended Chauncey Billups’ ‘rigged poker games’
- Baxter stock slides as Q3 sales come up short, guidance lowered
- Chipotle’s Stock Plunges 18% On Lowered Guidance
- Disney Ended Doctor Who Partnership for These 3 Reasons